Edwards Lifesciences Corp
BMV:EW

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
BMV:EW
Watchlist
Price: 2 196.53 MXN 1.7%
Market Cap: Mex$68.1B

Net Margin

23.2%
Current
Declining
by 19.3%
vs 3-y average of 42.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
23.2%
=
Net Income
$1.4B
/
Revenue
$5.9B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
23.2%
=
Net Income
Mex$1.4B
/
Revenue
$5.9B

Peer Comparison

Country Company Market Cap Net
Margin
US
Edwards Lifesciences Corp
NYSE:EW
47.5B USD
Loading...
US
Stryker Corp
NYSE:SYK
136.8B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
129.8B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
185.8B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
184.4B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
137.3B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
57.6B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
47.7B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
55B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.6B USD
Loading...
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
36.3B USD
Loading...

Market Distribution

Higher than 87% of companies in the United States of America
Percentile
87th
Based on 15 072 companies
87th percentile
23.2%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Edwards Lifesciences Corp
Glance View

Nestled at the intersection of medical innovation and patient care, Edwards Lifesciences Corp. has long been a pioneer in the field of heart disease solutions. Emerging from its origins in the 1950s, the company has consistently focused on advancing heart valve technology, a critical area given the prevalence and severity of cardiovascular diseases. Their journey began with the development of the first artificial heart valve, setting a foundation of innovation that continues to propel the company forward. Today, Edwards is renowned for its leadership in transcatheter aortic valve replacement (TAVR) technology, an area that revolutionizes the treatment of aortic stenosis, a condition that narrows heart valves and impedes blood flow. This shift from open-heart surgeries to less invasive procedures, facilitated by Edwards' products, has marked a significant turning point in patient care, minimizing recovery times and enhancing patient outcomes. Financially, Edwards Lifesciences thrives on a robust business model centered around its technologically advanced heart valve systems and critical care technologies. The company operates through a direct sales force as well as strategic partnerships, ensuring their devices reach hospitals and healthcare providers globally. Their commitment to research and development ensures a steady pipeline of innovative products, which not only differentiates them in the market but also drives their profitability. Revenue streams are primarily fueled by the sales of their TAVR systems, surgical heart valves, and monitoring technologies—each designed to meet the complex and evolving needs of patients with structural heart diseases. By continually investing in cutting-edge technology and expanding their global reach, Edwards Lifesciences not only supports its bottom line but also positions itself as a leader in the transformative field of medical device innovation.

EW Intrinsic Value
1 526.2 MXN
Overvaluation 31%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
23.2%
=
Net Income
$1.4B
/
Revenue
$5.9B
What is Edwards Lifesciences Corp's current Net Margin?

The current Net Margin for Edwards Lifesciences Corp is 23.2%, which is below its 3-year median of 42.5%.

How has Net Margin changed over time?

Over the last 3 years, Edwards Lifesciences Corp’s Net Margin has decreased from 27.2% to 23.2%. During this period, it reached a low of 23.2% on Sep 30, 2025 and a high of 76.7% on Dec 31, 2024.

Back to Top